Which laboratory tests are most important to monitor in a neonatal intensive care unit (NICU)?

Most Important Laboratory Tests to Monitor in the NICU

Blood glucose monitoring is the single most critical laboratory test in the NICU, as both hyperglycemia >8 mmol/L (145 mg/dL) and hypoglycemia ≤2.5 mmol/L (45 mg/dL) are directly associated with increased morbidity and mortality. 111

Priority Laboratory Monitoring Framework

1. Blood Glucose (Highest Priority)

Use blood gas analyzers for glucose measurement—not handheld meters—as they provide the most accurate results in newborns. 11 Handheld meters are unreliable due to interference from high hemoglobin and bilirubin levels common in neonates.

Critical thresholds:

• Avoid hyperglycemia >8 mmol/L (145 mg/dL) - associated with increased morbidity and mortality 11
• Treat repetitive levels >10 mmol/L (180 mg/dL) with insulin after adjusting glucose infusion rate 11
• Avoid hypoglycemia ≤2.5 mmol/L (45 mg/dL) - repetitive or prolonged episodes must be prevented 12

Monitoring frequency: In infants receiving resuscitation or at risk, 8-24% develop hypoglycemia in the first 6 hours, with 92% of critically ill infants showing hypoglycemia if measured in the delivery room 2

2. Bilirubin (Second Priority)

Measure total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) on every jaundiced infant in the first 24 hours. 33 Visual estimation is unreliable, especially in darkly pigmented infants.

When to measure:

• Any jaundice in first 24 hours 33
• Jaundice appearing excessive for infant's age 33
• Infants receiving phototherapy or with rapidly rising TSB 33
• At or beyond 3 weeks: measure total AND direct/conjugated bilirubin to identify cholestasis 33

Additional workup for unexplained or severe hyperbilirubinemia:

• Blood type and Coombs' test
• Complete blood count and smear
• Direct/conjugated bilirubin
• Consider: reticulocyte count, G6PD, albumin 33

3. Complete Blood Count (CBC)

Draw initial CBC from umbilical cord blood at birth when NICU admission is anticipated—this avoids blood volume loss and pain from infant phlebotomy while providing valuable diagnostic information. 4

CBC provides critical information for:

• Anemia detection (60% of infants with inherited metabolic disorders present with anemia) 5
• Infection/sepsis evaluation
• Hemolytic disease assessment
• Baseline hematologic status

Important caveat: Point-of-care CBC testing (e.g., Sight OLO®) shows good agreement with laboratory analyzers for hemoglobin and hematocrit (CCC >0.97), but use arterial-venous samples, not capillary samples, for accuracy 678

4. Electrolytes and Blood Gas Analysis

Point-of-care blood gas analyzers provide rapid, accurate results for:

• Sodium, potassium, chloride (though POC sodium differs by ~6 mEq/L from central lab) 8
• pH and acid-base status
• Lactate levels

Red flags requiring metabolic workup:

• Hyperammonemia (61.5% of inherited metabolic disorders) 5
• Metabolic acidosis (53.8% of inherited metabolic disorders) 5
• Respiratory alkalosis (16.9% of inherited metabolic disorders) 5

5. Newborn Screening and Metabolic Tests

For sick infants or those with unexplained clinical deterioration:

• Verify newborn screening results (thyroid, galactosemia) 33
• Consider expanded metabolic testing if clinical suspicion exists 95
• Acylcarnitine profile for suspected fatty acid oxidation disorders 9

Key Clinical Pitfalls to Avoid

1. Don't rely on handheld glucose meters in critically ill neonates—high bilirubin and hemoglobin cause false readings 11

2. Don't use visual assessment alone for jaundice—particularly unreliable in darkly pigmented infants 33

3. Don't use capillary samples for POC hemoglobin testing—they show significant discrepancies compared to laboratory results 6

4. Don't delay bilirubin measurement beyond 24 hours in jaundiced infants—interpret all levels according to infant's age in hours 33

5. Don't ignore family history—75.3% of infants with inherited metabolic disorders have consanguineous parents, and 27.6% have affected siblings 5

Practical Implementation

Minimize unnecessary testing while maintaining safety: Quality improvement initiatives have demonstrated 26.8% reductions in laboratory testing without adverse effects by using targeted guidelines and expanding point-of-care testing 10. However, the core tests above (glucose, bilirubin, CBC, basic metabolic panel) remain essential for detecting life-threatening conditions that directly impact mortality and neurodevelopmental outcomes.